Found: 34
Select item for more details and to access through your institution.
PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-13102-7
- By:
- Publication type:
- Article
Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR -mutant lung adenocarcinoma treated with first-line osimertinib.
- Published in:
- Therapeutic Advances in Medical Oncology, 2024, p. 1, doi. 10.1177/17588359231220606
- By:
- Publication type:
- Article
Pulmonary aspergillosis in an immunocompetent patient.
- Published in:
- Brazilian Journal of Infectious Diseases, 2013, v. 17, n. 3, p. 375, doi. 10.1016/j.bjid.2012.09.016
- By:
- Publication type:
- Article
The JMJD6/HURP axis promotes cell migration via NF‐κB‐dependent centrosome repositioning and Cdc42‐mediated Golgi repositioning.
- Published in:
- Journal of Cellular Physiology, 2022, v. 237, n. 12, p. 4517, doi. 10.1002/jcp.30900
- By:
- Publication type:
- Article
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma.
- Published in:
- Cancer Research & Treatment, 2022, v. 54, n. 2, p. 434, doi. 10.4143/crt.2021.671
- By:
- Publication type:
- Article
Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment.
- Published in:
- Cancer Research & Treatment, 2018, v. 50, n. 4, p. 1164, doi. 10.4143/crt.2017.460
- By:
- Publication type:
- Article
The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma.
- Published in:
- Cancer Research & Treatment, 2018, v. 50, n. 4, p. 1294, doi. 10.4143/crt.2017.512
- By:
- Publication type:
- Article
The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, v. 13, p. 1, doi. 10.1177/17588359211018022
- By:
- Publication type:
- Article
The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211018022
- By:
- Publication type:
- Article
Identification of Five Driver Gene Mutations in Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan.
- Published in:
- PLoS ONE, 2015, v. 10, n. 3, p. 1, doi. 10.1371/journal.pone.0120852
- By:
- Publication type:
- Article
Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma.
- Published in:
- PLoS ONE, 2014, v. 9, n. 9, p. 1, doi. 10.1371/journal.pone.0107160
- By:
- Publication type:
- Article
Association of Smoking With Patient Characteristics and Outcomes in Small Cell Lung Carcinoma, 2011-2018.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 3, p. e224830, doi. 10.1001/jamanetworkopen.2022.4830
- By:
- Publication type:
- Article
Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 1, p. 231, doi. 10.3390/jcm12010231
- By:
- Publication type:
- Article
Influence of the Timing of Leptomeningeal Metastasis on the Outcome of EGFR -Mutant Lung Adenocarcinoma Patients and Predictors of Detectable EGFR Mutations in Cerebrospinal Fluid.
- Published in:
- Cancers, 2022, v. 14, n. 12, p. 2824, doi. 10.3390/cancers14122824
- By:
- Publication type:
- Article
Landscape of Mitochondria Genome and Clinical Outcomes in Stage 1 Lung Adenocarcinoma.
- Published in:
- Cancers, 2020, v. 12, n. 3, p. 755, doi. 10.3390/cancers12030755
- By:
- Publication type:
- Article
EGFR mutation and lobar location of lung adenocarcinoma.
- Published in:
- Carcinogenesis, 2016, v. 37, n. 2, p. 157, doi. 10.1093/carcin/bgv168
- By:
- Publication type:
- Article
The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-91657-7
- By:
- Publication type:
- Article
Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-89043-4
- By:
- Publication type:
- Article
ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41598-020-78152-1
- By:
- Publication type:
- Article
Procalcitonin is a valuable prognostic marker in ARDS caused by community-acquired pneumonia.
- Published in:
- Respirology, 2008, v. 13, n. 4, p. 505, doi. 10.1111/j.1440-1843.2008.01293.x
- By:
- Publication type:
- Article
Outcome of Thromboembolic Events and Its Influence on Survival Time of Advanced NSCLC Patients Treated with Antiangiogenic Therapy.
- Published in:
- Cancer Management & Research, 2023, v. 15, p. 1251, doi. 10.2147/CMAR.S430868
- By:
- Publication type:
- Article
Various impacts of driver mutations on the PD-L1 expression of NSCLC.
- Published in:
- PLoS ONE, 2022, v. 17, n. 8, p. 1, doi. 10.1371/journal.pone.0273207
- By:
- Publication type:
- Article
Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan.
- Published in:
- Targeted Oncology, 2022, v. 17, n. 3, p. 295, doi. 10.1007/s11523-022-00878-x
- By:
- Publication type:
- Article
Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment.
- Published in:
- Oncology, 2021, v. 99, n. 1, p. 32, doi. 10.1159/000509664
- By:
- Publication type:
- Article
Comprehensive Analysis and Risk Identification of Pulmonary Cryptococcosis in Non-HIV Patients.
- Published in:
- Journal of Fungi, 2021, v. 7, n. 8, p. 1, doi. 10.3390/jof7080657
- By:
- Publication type:
- Article
Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1096683
- By:
- Publication type:
- Article
Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma.
- Published in:
- OncoTargets & Therapy, 2014, v. 7, p. 799, doi. 10.2147/OTT.S62639
- By:
- Publication type:
- Article
Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma.
- Published in:
- PLoS ONE, 2018, v. 13, n. 11, p. 1, doi. 10.1371/journal.pone.0207001
- By:
- Publication type:
- Article
Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR -Mutant Lung Adenocarcinoma.
- Published in:
- Medicina (1010660X), 2022, v. 58, n. 7, p. N.PAG, doi. 10.3390/medicina58070908
- By:
- Publication type:
- Article
Attenuation of PI3K-Akt-mTOR Pathway to Reduce Cancer Stemness on Chemoresistant Lung Cancer Cells by Shikonin and Synergy with BEZ235 Inhibitor.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 1, p. 616, doi. 10.3390/ijms25010616
- By:
- Publication type:
- Article
The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib.
- Published in:
- OncoTargets & Therapy, 2023, v. 16, p. 317, doi. 10.2147/OTT.S407301
- By:
- Publication type:
- Article
Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients.
- Published in:
- OncoTargets & Therapy, 2021, v. 14, p. 2139, doi. 10.2147/OTT.S300267
- By:
- Publication type:
- Article